The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
AUA 2025 – J&J scores in a new bladder cancer use
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Xencor could face second challenge from former partner
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
